Showing results (181-190 of 430) with videos related to
Sort By:
Pageof 43
JACC. Heart Failure|April 4, 2016
QRS Duration Is a Predictor of Adverse Outcomes in Heart Failure With Preserved Ejection FractionJacob Joseph, Brian C Claggett, Inder S Anand, et al.American Heart Journal|August 17, 2004
Antecedent hypertension and the effect of captopril on the risk of adverse cardiovascular outcomes after acute myocardial infarction with left ventricular systolic dysfunction: Insights from the Survival and Ventricular Enlargement TrialSatish Kenchaiah, Barry R Davis, Eugene Braunwald, et al.Circulation. Heart Failure|December 6, 2012
Effect of cardiac stem cells on left-ventricular remodeling in a canine model of chronic myocardial infarctionFrederick G P Welt, Robert Gallegos, John Connell, et al.The Lancet. Diabetes & Endocrinology|January 18, 2016
Renal outcomes with aliskiren in patients with type 2 diabetes: a prespecified secondary analysis of the ALTITUDE randomised controlled trialHiddo J L Heerspink, Frederik Persson, Barry M Brenner, et al.Journal of Cardiac Failure|May 31, 2022
Prognostic Impact of Cardiovascular Versus Noncardiovascular Hospitalizations in Heart Failure With Preserved Ejection Fraction: Insights From TOPCATEbrahim Barkoudah, Brian L Claggett, Eldrin F Lewis, et al.Clinical Journal of the American Society of Nephrology : CJASN|January 8, 2011
Darbepoetin alfa impact on health status in diabetes patients with kidney disease: a randomized trialEldrin F Lewis, Marc A Pfeffer, Amy Feng, et al.Circulation|February 24, 2010
Mechanical dyssynchrony after myocardial infarction in patients with left ventricular dysfunction, heart failure, or bothSung-Hee Shin, Chung-Lieh Hung, Hajime Uno, et al.Circulation. Heart Failure|January 21, 2020
Mechanistic Effects of Spironolactone on Cardiovascular and Renal Biomarkers in Heart Failure With Preserved Ejection Fraction: A TOPCAT Biorepository StudyPeder L Myhre, Muthiah Vaduganathan, Eileen O'Meara, et al.JACC. Heart Failure|April 1, 2017
Interaction Between Spironolactone and Natriuretic Peptides in Patients With Heart Failure and Preserved Ejection Fraction: From the TOPCAT TrialInder S Anand, Brian Claggett, Jiankang Liu, et al.Journal of the American College of Cardiology|April 15, 2014
Fibroblast growth factor-23, cardiovascular prognosis, and benefit of angiotensin-converting enzyme inhibition in stable ischemic heart diseaseJacob A Udell, David A Morrow, Petr Jarolim, et al.Pageof 43